The invention is related to association products of xanthates and cyclodextrins, pharmaceutical formulations made therefrom, and medicaments containing these formulations for treating Alzheimer's, viral, tumor, cardiovascular, and autoimmune diseases such as rheumatism, multiple sclerosis, alopecia areata, lupus erythematosus, stroke, lung edema, or for use as radio-protectors. The association products contain a xanthate of general formula I whereby R1 represents a possibly substituted aryl or alkyl residue and R2 represents a metal atom, a possibly substituted alkyl, alkoxy, amino or ammonium group or halogen, and a cyclodextrin, whereby the cyclodextrin can be either a substituted or non-substituted alpha-, beta- or gamma-cyclodextrin. Furthermore, the invention is related to the use of the association products for chemical syntheses.